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Objective: Aberrant hepatic glucose production contributes to the development of hyperglycemia and is a hallmark of type 2 diabetes. In a recent
study, we showed that the transcription factor E2F1, a component of the cell cycle machinery, contributes to hepatic steatosis through the
transcriptional regulation of key lipogenic enzymes. Here, we investigate if E2F1 contributes to hyperglycemia by regulating hepatic
gluconeogenesis.
Methods: We use different genetic models to investigate if E2F1 regulates gluconeogenesis in primary hepatocytes and in vivo. We study the
impact of depleting E2F1 or inhibiting E2F1 activity in diabetic mouse models to evaluate if this transcription factor contributes to hyperglycemia
during insulin resistance. We analyze E2F1 mRNA levels in the livers of human diabetic patients to assess the relevance of E2F1 in human
pathophysiology.
Results: Lack of E2F1 impaired gluconeogenesis in primary hepatocytes. Conversely, E2F1 overexpression increased glucose production in
hepatocytes and in mice. Several genetic models showed that the canonical CDK4-RB1-E2F1 pathway is directly involved in this regulation. E2F1
mRNA levels were increased in the livers from human diabetic patients and correlated with the expression of the gluconeogenic enzyme Pck1.
Genetic invalidation or pharmacological inhibition of E2F1 improved glucose homeostasis in diabetic mouse models.
Conclusions: Our study unveils that the transcription factor E2F1 contributes to mammalian glucose homeostasis by directly controlling hepatic
gluconeogenesis. Together with our previous ﬁnding that E2F1 promotes hepatic steatosis, the data presented here show that E2F1 contributes to
both hyperlipidemia and hyperglycemia in diabetes, suggesting that speciﬁcally targeting E2F1 in the liver could be an interesting strategy for
therapies against type 2 diabetes.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Sustaining blood glucose levels within a relatively narrow range is
essential for maintaining global homeostasis. This status is achieved
through a complex balance between glucose production and utilization
by different tissues. These processes are dynamically regulated by
hormonal and nutritional signals [1]. Hepatic glucose production, which
comprises glycogenolysis and gluconeogenesis (de novo production of
glucose from non-carbohydrate substrates), is critical for adaptation to
fasting conditions and represents up to 80% of total endogenous
glucose production [2]. Hepatic gluconeogenesis is largely controlled
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glucose-6-phosphatase (G6PC), which catalyze the ﬁrst committed
steps and the terminal steps of gluconeogenesis, respectively. Several
transcription factors and coactivators, control the expression of these
gluconeogenic enzymes in response to hormones, especially insulin
and glucagon [1]. Aberrant regulation of hepatic glucose production is
a major contributor to the hyperglycemia observed in type 2 diabetes
and the insulin-resistant state. Indeed, clinical suppression of hepatic
glucose production to lower glycemia is one of the main targets of
diabetes treatment [2]. In normal subjects, hepatic gluconeogenesis
and lipogenesis are mutually exclusive events. In contrast, during
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as well as high levels of cholesterol and triglyceride synthesis,
resulting in both dyslipidemia and hyperglycemia. This highlights the
apparent paradox of selective insulin resistance in the liver [3].
Although some explanations have been proposed, this phenomenon is
not yet fully understood [4,5].
E2F transcription factors are the downstream effectors of distinct
signaling cascades that regulate the expression of genes involved in
cellular homeostasis. In proliferating cells, E2F target genes include
effectors of DNA replication, mitosis, DNA repair, and apoptosis [6].
E2Fs exist either as heterodimers associated with dimerization partner
(DP) proteins or within larger complexes, including members of the
retinoblastoma family of proteins (pRBs). In general, the association of
E2Fs with pRB family members induces the repression of their target
genes. When phosphorylated by active cyclinecyclin-dependent ki-
nase (CDK) complexes, pRBs are released, enabling E2Fs to drive
transcriptional activation [6].
We have previously demonstrated that E2F1, the ﬁrst member of the
E2F family to be described and studied extensively, has important
metabolic functions beyond the control of the cell cycle in non-
proliferating cells [7e9]. Studies of the retinoblastoma protein RB1
further support a major role of E2F1 in metabolism [10]. In recent
studies, we showed that E2F1 is essential for controlling liver meta-
bolism, regulating cholesterol uptake and promoting lipid synthesis
through transcriptional regulation of key lipogenic enzymes [11,12].
We also highlighted that widely used animal models of non alcoholic
fatty liver disease (NAFLD) had increased levels of E2f1 expression and
activity in the liver [12]. Here, we demonstrate that E2F1 contributes to
mammalian glucose homeostasis through the control of hepatic
glucose production. Importantly, our results indicate that E2F1 is
critical for inducing hyperglycemia in type 2 diabetes. This suggests
that reducing E2F1 activity could protect against obesity-induced
hyperglycemia.
2. MATERIALS AND METHODS
Animal experiments. C57BL/6J mice were purchased from Janvier
Labs (Le Genest-Saint-Isle, France). E2f1/ (B6; 129S4-
E2f1tm1Meg/J) mice and db/þ mice (Janvier Labs) were crossed to
obtain db/db; E2f1þ/ mice. E2F1tg/þ mice harboring the Rosa26-
loxP-LacZ-LoxP-E2F1 conditional expression cassette were obtained
from Ulrike Ziebold (MDC, Berlin, Germany) [13]. E2F1tg/þ mice were
crossed with Alb-creþ mice to obtain E2F1tg/þ Alb-Creþ mice and
their control littermates E2F1tg/þ Alb-Cre- mice. E2f1ﬂ/ﬂ mice
(Taconic Biosciences, NY, USA) were crossed with Alb-creþ mice to
obtain E2f1ﬂ/ﬂ Alb-Creþ (E2f1-LKO) and their control littermates
E2f1ﬂ/ﬂ Alb-Cre- mice. Mice were housed under a 12-hour light/dark
cycle and sacriﬁced as indicated. For high fat diet (HFD) experiments,
mice were fed during 12 or 16 weeks, as indicated, with a HFD
(2127, Kliba Nafag or TD06414, Envigo). For pharmacological inhi-
bition of E2F, during the last 10 days of the HFD, mice were gavaged
daily with 40 mg/kg of E2F inhibitor HLM006474 (324461, Merck-
Millipore) or vehicle. For Pyruvate tolerance test (PTT), mice were
fasted overnight and injected with pyruvate (1 g/kg). For insulin
tolerance test (ITT), mice were fasted for 6 h and injected with in-
sulin 0.75 U/kg (Actrapid, Novonordisk). Blood glucose was deter-
mined using a glucometer and glucose strips (Accu-Chek Aviva,
Roche). Serum levels of lactate dehydrogenase, ALT and AST were
measured by the Mouse Metabolic Facility of the University of Lau-
sanne. All animal experiments were performed according to Swiss
animal welfare laws and were approved by the Canton of Vaud SCAV
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Culture Collection (ATCC). E2F1/ HepG2 cells were described here
[11]. Primary hepatocytes were isolated as previously described [14].
Primary hepatocytes were isolated from C57Bl/6J mice, E2f1/ mice
(B6; 129S4-E2f1tm1Meg/J), E2F1tg/þ crossed with Abl-Creþ mice,
Rb1ﬂ/ﬂ mice (B6,129-Rb1tm3Tyj/J) crossed with Abl-Creþ mice, Cdk4/
 mice, and Cdk4R24C/R24C mice [15] and their respective control mice.
C57Bl/6J hepatocytes were not used as controls for mutant hepato-
cytes. Mouse hepatocytes were isolated, cultured, and infected with
adenoviruses Ad-GFP and Ad-E2F1, as previously described [12,14].
For mRNA expression experiments, primary hepatocytes were treated
for 3 h with 10 mM Forskolin (Cat. F6886, Sigma-Aldrich) or vehicle
(DMSO). For glucose production experiments, hepatocytes were rinsed
twice with PBS and cultured in media without glucose, glutamine, and
phenol red (Cat. A14430, Life Technologies) supplemented with
10 mM sodium lactate, 1 mM sodium pyruvate, and forskolin (10 mM).
After 6 h, media was collected for glucose quantiﬁcation (Cat. GAGO20,
Sigma-Aldrich) and proteins were quantiﬁed for normalization.
Real-time quantitative PCR analysis. Total mRNA was extracted
from 20 to 30 mg of mouse liver or cultured cells using an RNeasy kit
(Cat: 74106, Qiagen) according to the manufacturer’s protocol. One
microgram of the RNA was subsequently reverse-transcribed and
quantiﬁed via real-time quantitative PCR using an ABI 7900HT in-
strument. Gene expressions were determined using the delta Ct
method or the standard curve method normalized housekeeping gene
ribosomal protein S9 (RS9) levels. The complete list of primers is
presented in Supplemental Table 2.
Seahorse analyses. Mitochondrial function was determined with an
XF-24 extracellular ﬂux analyzer (Seahorse Bioscience). Oxygen con-
sumption Rate (OCR) was measured in control and mutant hepatocytes
that were seeded in an XF 24-well cell culture microplate 16 h before
the experiment. OCR was expressed as pmol of O2 per minute and was
normalized by protein content. Just before the experiment the cells
were washed, and the hepatocyte culture medium was replaced with
KHB containing 2.5 mM Glucose and 1.5 mM of carnitine. After
measuring baseline OCR as an indication of basal respiration, OCR was
measured after an acute injection of 300 mM of palmitate coupled to
BSA.
ChIP experiment. ChIP was performed as previously described [16].
The sheared DNA was immunoprecipitated by an E2F1 antibody (Cat.
3742, Cell Signaling Technology) coupled to magnetic beads. The
immunoprecipitated chromatin was washed, reverse cross-linked at
65C overnight and puriﬁed using minielute columns (Cat. 28006,
Qiagen). Finally, E2F1 DNA binding was quantiﬁed via real-time
quantitative PCR using an ABI 7900HT instrument.
Immunoblotting. Total protein extract and immunoblot analysis were
performed as previously described [14]. The following antibodies were
used: E2F1 (Cat. 3742, Cell Signaling Technology), Ser780 phosphor-
ylated RB (Cat. 8180, Cell Signaling Technology), RB (Cat.C-15 Santa
Cruz Biotechnology), CREB (Cat. 9197, Cell Signaling Technology),
Ser133 phosphorylated CREB (Cat. 9198, Cell Signaling Technology),
and beta-ACTIN (Cat. A2066, Sigma-Aldrich).
Human samples. All obese patients included in this study are from the
ABOS study (Atlas Biologique de l’Obésité Sévère). This study also
included a group of lean and normoglycemic control patients that had
surgery for benign and non-inﬂammatory pathologies. Clinical data
were collected at Centre Hospitalier Régional Universitaire de Lille. The
protocol concerning the use of biopsies from patients follows French
regulations and was approved by the Institutional Ethical Committee of
the University of Lille and the Centre Hospitalier Régional Universitaire
de Lille (ClinGov NCT 01129297). All patients gave written andccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 105
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Hba1c and high HOMA-IR. Metabolic parameters of the two groups are
presented in Supplemental Table 1. Liver samples were collected
during surgery, within the ﬁrst 15 min of the procedure, weighed and
snap-frozen in liquid nitrogen. Total RNA and protein were extracted
from 10 mg of liver samples using the All in One Puriﬁcation Kit
(NorGen Biotek Corp). First-strand cDNA synthesis was performed
using 500 ng total RNA as a template and Superscript II reverse
transcriptase (Life Technologies) primed with 50 pmol of random
hexamers (New England Biolabs). Quantitative real-time PCR was
performed using the Bio-Rad MyiQ Single-Color Real-Time PCR
Detection System and the Bio-Rad iQ SYBR Green Supermix (Bio-Rad
Laboratories). Gene expression was normalized to two housekeeping
genes Beta-actin (Actb) and ribosomal protein S9 (RS9).
Statistical analysis. All data are expressed as the mean  SEM
except human data. Statistical signiﬁcance was assessed with un-
paired t-test using Prism 7 software (GraphPad Software, La Jolla, CA
USA). The correlation analysis was performed using Pearson correla-
tion test. Differences were considered statistically signiﬁcant at
P < 0.05.
3. RESULTS
3.1. Lack of E2F1 blunts hepatic gluconeogenesis in hepatocytes
We have recently shown that the cell cycle regulator E2F1 promotes
hepatic lipogenesis during insulin resistance. We wondered if E2F1
could participate in glucose production in the liver, a metabolic
pathway that is abnormally active in type 2 diabetes. For this purpose,
we analyzed the gluconeogenic capacity of primary hepatocytes
lacking E2F1. Mouse primary hepatocytes obtained from E2f1/mice
and their wild type littermates were treated with forskolin, a protein
kinase A (PKA) activator that mimics glucagon action in the liver by
increasing cAMP levels, to activate gluconeogenesis. Pck1 and G6pc
mRNA expression levels were signiﬁcantly reduced in E2f1/ hepa-
tocytes after forskolin stimulation (Figure 1A). This led to a decrease in
glucose production in E2f1-deﬁcient primary hepatocytes (Figure 1B).
No differences between the two genotypes were observed in basal
conditions, when gluconeogenic gene expression is very low (data not
shown). Similarly, depleting E2F1 in HepG2 cells, a human hepatoma
cell line, using CRISPR/Cas9 technology resulted in a signiﬁcant
decrease in gluconeogenic gene expression (Figure 1C,D).
Gluconeogenesis is an energy-consuming process that requires intact
mitochondrial function. In fasting conditions, fatty acids produced by
the lipolysis in white adipose tissue are oxidized in the liver to sustain
gluconeogenesis [1]. We have previously shown that E2F1 regulates
oxidative metabolism [8]. This prompted us to investigate if the
decrease in gluconeogenesis observed in E2f1/ hepatocytes could
be due to a defect in mitochondrial oxidation of fatty acids. Seahorse
analyses showed that E2f1-deﬁcient primary hepatocytes presented
increased fatty acid oxidation (Figure 1E,F), which indicated that the
decrease in glucose production observed in E2f1/ hepatocytes was
not caused by impaired mitochondrial function.
The above ﬁndings showed that lack of E2F1 in hepatocytes impairs
glucose production due to a decrease in gluconeogenic gene
expression.
3.2. Overexpression of E2F1 induces gluconeogenesis in primary
hepatocytes and in liver
To further examine whether E2F1 may promote gluconeogenesis, we
transduced mouse primary hepatocytes with an adenovirus over-
expressing human E2F1 (ad-E2F1). E2F1 overexpression markedly106 MOLECULAR METABOLISM 11 (2018) 104e112  2018 The Authors. Published by Elsevier GmbH.increased Pck1 mRNA levels, which led to a concomitant increment in
glucose production (Figure 2A,B). In contrast to what was observed in
E2f1/ hepatocytes, E2F1 overexpression had no major effect on
G6pc mRNA levels (Figure 2A). The effect of E2F1 overexpression on
gluconeogenesis was completely abrogated in the presence of the PKA
inhibitor H89 (Figure 2A,B). These results suggested that E2F1 pro-
motes gluconeogenesis in a PKA-dependent manner.
To investigate if E2F1 could promote hepatic gluconeogenesis in vivo,
we generated a liver-speciﬁc E2F1 overexpressing mouse model by
crossing transgenic mice harboring the Rosa26-loxP-LacZ-LoxP-E2F1
conditional expression cassette (E2F1tg/þ mice) [13] with Alb-Cre
mice. Under Cre recombinase activity, these mice express human
E2F1 under the control of the Rosa promoter, which results in a mild
increase in hepatic E2F1 protein levels (Suppl. Fig. 1A). When chal-
lenged with a pyruvate tolerance test, which reﬂects hepatic gluco-
neogenesis, hepatic glucose production increased to a much greater
extent in E2F1tg/þ Alb-Creþ mice compared to their control littermates
(Figure 2C). Remarkably, this increase was not due to a defect in in-
sulin sensitivity (Suppl. Fig. 1B). Similar to what we observed in pri-
mary hepatocytes infected with ad-E2F1 (Figure 2A), transgenic mice
overexpressing E2F1 in the liver presented higher hepatic Pck1 mRNA
levels, but no changes in G6pc mRNA (Figure 2D). In addition, primary
hepatocytes isolated from E2F1tg/þ Alb-Creþmice presented the same
pattern of gluconeogenic gene expression, and increased glucose
production (Figure 2E,F). No differences were observed in terms of
fatty acid oxidation (Suppl. Fig. 1C-D). Altogether, these results
showed that increasing E2F1 levels in the liver is sufﬁcient to promote
hepatic gluconeogenesis in vivo.
We next performed chromatin immunoprecipitation (ChIP) to examine
whether E2F1 is recruited to the promoters of gluconeogenic genes.
Immunoprecipitation of endogenous E2F1 from the livers of mice led to
an enrichment of the proximal region of the Pck1 promoter (Figure 2G).
No signiﬁcant binding of E2F1 was observed in the promoter of G6pc.
Notably, the enrichment in the Pck1 promoter was higher during fasting
conditions, whereas no differences due the nutritional status where
observed in the binding of E2F1 to its own promoter. Moreover, pro-
moter analysis revealed the presence of putative E2F response ele-
ments in the mouse and human PCK1 promoters (Suppl. Fig 2A). These
results suggested that E2F1 directly activates the expression of PCK1.
Lack of E2F1 caused a marked decrease of G6pc expression (Figure 1),
but we were not able to detect a signiﬁcant binding of E2F1 to its
promoter (Figure 2G). This prompted us to investigate if E2F1 could
also regulate gluconeogenesis by affecting the PKA pathway. In the
cAMP/PKA pathway, cAMP elevation in response to glucagon leads to
activation of serine kinase PKA, which phosphorylates the transcription
factor CREB on Serine133. Phosphorylated CREB promotes gluconeo-
genesis through the induction of Pck1 and G6pc transcription [1]. CREB
phosphorylation was examined in E2f1/ primary hepatocytes after
forskolin stimulation. The phosphorylation signal was signiﬁcantly
reduced in E2f1/ hepatocytes indicating a decrease in PKA activity
(Suppl. Fig. 2B). On the contrary, E2F1 adenoviral transduction in
hepatocytes led to exacerbated CREB Serine133 phosphorylation at
(Suppl. Fig 2C). To assess if E2F1 also enhanced PKA signaling in vivo,
we evaluated the phosphorylation status of CREB in the livers of fasted
E2F1tg/þ Alb-Creþ mice. No differences were observed in the phos-
phorylation of CREB in mice overexpressing E2F1 in the liver
(Suppl. Fig 1E).
The above results suggested that E2F1 promotes gluconeogenesis in
hepatocytes directly by regulating PCK1 expression and indirectly by
modulating the activity of the PKA pathway. Nevertheless, in vivo the
















Figure 1: E2F1 deﬁciency reduces gluconeogenesis in hepatocytes. (A) Relative expression levels of Pck1 and G6pc mRNA in primary hepatocytes from E2f1þ/þ and E2f1/
mice treated for 3 hours with 10 mM forskolin (Fsk). (B) Glucose production by E2f1þ/þ and E2f1/ primary hepatocytes treated for 6 hours with 10 mM Fsk (n ¼ 3). (C) E2F1
protein levels in E2F1þ/þ and E2F1/ HepG2 cells. (D) Relative expression levels of PCK1 and G6PC mRNA in E2F1þ/þ and E2F1/ HepG2 cells incubated overnight in a serum-
free medium and treated for 3 hours with forskolin (10 mM) (n ¼ 3). (E) Fatty acid oxidation in E2f1þ/þ and E2f1/ primary hepatocytes. (F) Quantiﬁcation of the area under curve
of the palmitate induced OCR. Data represent the mean  SEM. *P < 0.05, **P < 0,01, (2-tailed, unpaired t test).3.3. The CDK4/RB1 pathway participates with E2F1 in the control
of gluconeogenesis
Given that E2F1 modulates gluconeogenesis in a PKAedependent
manner (Figure 2A,B), we wanted to determine whether CDK4 and
RB1, upstream regulators of E2F1, participated in the control of
gluconeogenesis. CDK4, when associated with the regulatory D-type
cyclins, promotes E2F1 transcriptional activity by phosphorylating RB1
and therefore releasing E2F1 from its repression [6]. We have previ-
ously shown that CDK4 can be activated in response to insulin, both in
adipocytes [17] and in hepatocytes [12]. We investigated next, whether
the gluconeogenic hormone glucagon could modulate the CDK4/RB1
pathway in hepatocytes. We observed an increase in RB1 Ser780
phosphorylation in response to glucagon stimulation in primary he-
patocytes (Figure 3A). The same observation was conﬁrmed in HepG2
cells in response to forskolin stimulation (Figure 3B), which suggests a
PKA-dependent activation of CDK4. This dual phosphorylation of RB1
both by insulin and by glucagon in primary hepatocytes was also
reproduced in HepG2 cells (Suppl. Fig. 3A-B). These results suggestedMOLECULAR METABOLISM 11 (2018) 104e112  2018 The Authors. Published by Elsevier GmbH. This is an open a
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to promote the expression of gluconeogenic genes. Consistently,
Rb1/ hepatocytes showed higher expression levels of Pck1 and
G6Pc mRNAs and a concomitant increase in glucose production
(Figure 3C,D), which was the reverse phenotype of hepatocytes lacking
E2F1 (Figure 1A and B).
Furthermore, primary hepatocytes isolated from Cdk4/ mice
(Figure 3E,F) or with depleted Cdk4 expression by shRNA
(Suppl. Fig. 3C-D) showed decreased gluconeogenic gene expression
and glucose production. In a complementary approach, we charac-
terized the gluconeogenic capacity of primary hepatocytes isolated
from Cdk4R24C/R24C mice, which express a mutant CDK4 protein that is
not sensitive to INK4 inhibitors and that is consequently more active
[15]. In sharp contrast with hepatocytes lacking CDK4 activity,
Cdk4R24C/R24C hepatocytes had an increased gluconeogenic proﬁle,
namely higher Pck1 and G6pc gene expression and increased glucose
production (Figure 3G,H). This is in agreement with the observation
that p16 (INK4a) deﬁciency enhances hepatic gluconeogenesis [18].ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 107
Figure 2: Overexpression of E2F1 induces gluconeogenesis in hepatocytes and in mice. (A) Relative expression levels of Pck1 and G6pc mRNA and (B) glucose production in
primary hepatocytes infected with ad-GFP or ad-E2F1 for 48 hours and treated with forskolin (10 mM) in the presence or absence of the PKA inhibitor H89 (5 mM). (C) Pyruvate
tolerance test (n ¼ 6e11) and (D) relative liver expression of Pck1 and G6pc mRNA of E2F1tg/þ Alb-Creþ and control mice (n ¼ 5). (E) Relative mRNA expression levels of Pck1 and
G6pc and (F) glucose production in primary hepatocytes from E2F1tg/þ Alb-Cre- and E2F1tg/þ Alb-Creþ mice after forskolin (10 mM) treatment. (G) E2F1 ChIP-qPCR on livers of
mice fasted for 24 hours or refed overnigt after a 24-hour fasting (n ¼ 4e6). Data represent the mean  SEM. *P < 0.05, ***P < 0,005 compared to control, # P < 0.05
compared to ad-E2F1 (2-tailed, unpaired t test).
Original ArticleCrucially, Cdk4R24C/R24C hepatocytes lacking E2f1 presented normal-
ized gluconeogenic gene expression levels and decreased glucose
production (Figure 3G,H), which revealed that CDK4 promoted gluco-
neogenesis in hepatocytes in an E2F1-dependent manner.
The above ﬁndings obtained in different genetic models that present an
alteration of the CDK4-RB1 pathway support the notion that E2F1
promotes gluconeogenesis in hepatocytes.108 MOLECULAR METABOLISM 11 (2018) 104e112  2018 The Authors. Published by Elsevier GmbH.3.4. E2F1 deﬁciency reduces gluconeogenesis in mouse models of
diabetes
Aberrant increased hepatic gluconeogenesis is the main contributor
to hyperglycemia during diabetes [2]. Mutants for the leptin receptor,
db/db mice have hyperphagia, obesity, and type 2 diabetes [19]. db/
db mice presented increased E2F1 mRNA and protein levels
(Figure 4B and Suppl. Fig 4A). In order to determine whether deletionThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 3: The CDK4/RB1 pathway participates with E2F1 in the control of gluconeogenesis. Ser780 phosphorylation of RB1 in (A) primary hepatocytes treated for 6 hours
with glucagon (100 nM) and (B) HepG2 cells treated for 2 hours with 10 mM forskolin (n ¼ 3). (C, E and G) Relative Pck1 and G6pc mRNA levels and (D, F and H) glucose
production in primary hepatocytes of the indicated genotypes (n ¼ 3) treated with Fsk for 3 or 6 hours, respectively. Data represent the mean  SEM. **P < 0.01, ***P < 0.005
compared to their controls. #P < 0.05, ##P < 0.01 compared to Cdk4R24C/R24C hepatocytes (2-tailed, unpaired t test).of E2f1 could decrease hyperglycemia in diabetic mouse models,
we generated db/db mice invalidated for one allele of E2f1: db/db
E2f1þ/. E2f1 homozygous mutants could not be used in this study
because db/db E2f1/ mice cannot produce sufﬁcient insulin due to
defective beta cell function [7,12]. db/db E2f1þ/ mice developed
obesity and became hyperinsulinemic like their db/db E2f1þ/þ lit-
termates (Suppl. Fig 4B,C) but presented E2f1 levels in the liver
comparable to non-diabetic mice (Figure 4B). Remarkably, partial
deletion of E2f1 in the db/db background was sufﬁcient to signiﬁ-
cantly decrease fasting blood glucose levels (Figure 4A). This was
associated with an almost complete normalization of Pck1 mRNA
levels and a signiﬁcant decrease of G6pc gene expression
(Figure 4B).
Next, in order to assess if the amelioration of hyperglycemia in db/db
mice lacking one copy of E2f1 was due to decreased E2F1 activity inMOLECULAR METABOLISM 11 (2018) 104e112  2018 The Authors. Published by Elsevier GmbH. This is an open a
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fed them with a high fat diet (HFD). HFD-induced obesity is
considered to be a more accurate representation of human type 2
diabetes onset [19]. After 12 weeks on this diet, E2f1 LKO mice
showed no differences in body weight compared to their wild-type
littermates (Suppl. Fig. 4D). However, E2f1 LKO mice presented
decreased fasting hyperglycemia (Figure 4C). After sacriﬁce, liver
gene expression was analyzed and E2f1 LKO mice showed a marked
decrease in gluconeogenic gene expression compared to their control
littermates (Figure 4D). Similarly to what we had observed in the
livers of E2F1tg/þ Alb-Creþ mice, the changes in hepatic gluconeo-
genic gene expression were not a consequence of differences in PKA
activity (Suppl. Fig 4F).
These results demonstrate that E2F1 contributes to hyperglycemia
during obesity by regulating hepatic gluconeogenesis.ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 109
Figure 4: E2F1 deﬁciency reduces hyperglycemia in diabetic mouse models. (A) Fasting glycemia and (B) relative liver mRNA expression levels of the indicated genes in db/þ
E2f1þ/þ, db/db E2f1þ/þ and db/db E2f1þ/ mice (n ¼ 5e10). (C) Fasting glycemia and (D) relative liver mRNA expression levels of the indicated genes in E2f1 LKO and control
mice fed for 12 weeks on high fat diet (n ¼ 6). Data represent the mean  SEM. *P < 0.05, **P < 0.01,***P < 0.005 (2-tailed, unpaired t test).
Figure 5: E2F1 expression is increased in diabetic patients and correlates with
PCK1 levels. (A) Relative expression of E2F1 mRNA in livers of lean subjects and obese
type 2 diabetic patients (n ¼ 10). Data represent the median with individual plots.
* P < 0.05 (2-tailed, unpaired t test). (B) Correlation between hepatic E2F1 and PEPCK1
mRNA levels in a cohort of human patients (n ¼ 38). A Pearson correlation analysis
was performed.
Original Article3.5. E2F1 mRNA expression is increased in the livers of diabetic
patients and correlates with PCK1 levels
Next, we sought to examine whether hepatic E2F1 could also contribute
to hyperglycemia in humans. For this purpose, we quantiﬁed E2F1
mRNA levels in liver biopsies from a cohort of 38 human patients (the
metabolic proﬁles of these patients are presented in Suppl. Table 1).
E2F1 mRNA levels were signiﬁcantly increased in the livers of obese
diabetic patients compared to lean patients (Figure 5A). Moreover,
analyzing liver gene expression in the whole cohort, we found a sig-
niﬁcant correlation between E2F1- and PCK1 mRNA levels (Figure 5B).
3.6. Pharmacological inhibition of E2F1 reduces hyperglycemia in
diabetic mice
Given that E2F1 contributes to hyperglycemia during insulin resistance
(Figure 4), we investigated whether targeting E2F1 activity could be
used to treat hyperglycemia in diabetic mice. First, mouse primary
hepatocytes were treated overnight with the E2F chemical inhibitor
HLM006474. This led to a decrease in glucose production that corre-
lated with impaired expression of gluconeogenic genes (Figure 6 A,B).
Next, wild-type mice fed with a HFD during 16 weeks were treated for
ten days with the same compound. Strikingly, treatment with the E2F
chemical inhibitor decreased hyperglycemia and completely normal-
ized gluconeogenic gene expression in the liver of this diabetic mouse
model (Figure 6 C,D). Noteworthy, the treatment did not have an impact
on the body weight of the mice or in the circulating levels of lactate
dehydrogenase and of the transaminases ALT and AST, which sug-
gested lack of hepatic toxicity (Suppl. Fig.5 A-C).
4. DISCUSSION
We report here that E2F1 is a major component of the transcriptional
response to induce hepatic gluconeogenesis and that this transcription110 MOLECULAR METABOLISM 11 (2018) 104e112  2018 The Authors. Published by Elsevier GmbH.factor plays a critical role in the pathophysiology of type 2 diabetes by
actively contributing to hyperglycemia in diabetic mouse models.
Importantly, we show that E2F1 gene expression is increased in hu-
man liver biopsies from diabetic patients and that it correlates with the
levels of PCK1, which is implicated in the development of hypergly-
cemia in mice [20] and probably also in humans [21]. Furthermore, we
identify that this regulation involves the canonical regulators of E2F1,
RB1 and CDK4.
The impact of modulating E2F1 activity on gluconeogenesis was only
evident in primary hepatocytes in conditions that mimic the liver during
fasting or in mice during insulin resistance. This suggests that the PKA
pathway somehow promotes E2F1 action during gluconeogenesis. In
this regard, we show that glucagon treatment leads to retinoblastoma
protein phosphorylation in hepatocytes (Figure 3). These ﬁndings areThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 6: Pharmacological inhibition of E2F1 reduces hyperglycemia in diabetic mice. (A) Relative expression levels of Pck1 and G6pc and (B) glucose production in primary
hepatocytes incubated overnight with DMSO or a E2F inhibitor (HLM006474, 25 mM) followed by forskolin treatment (10 mM) during 3 hours (n ¼ 4). (C) Fasting glycemia and (D)
relative liver mRNA expression levels of the indicated genes of mice fed during 16 weeks with a high-fat diet and treated 10 days with HLM006474 (40 mg/kg/day) or vehicle
(n ¼ 5e8). Data represent the mean  SEM. *P < 0.05, ***P < 0,005 (2-tailed, unpaired t test).consistent with previous studies in other tissues that have described a
PKA-dependent activation of CDK4 in thyroid cells [22] and increased
RB1 Ser780 phosphorylation in muscle in response to the administra-
tion of isoproterenol, a b-3 adrenergic agonist that also promotes PKA
activity [8]. Moreover, glucagon has been reported to induce, in a PKA-
dependent manner, chromatin epigenetic changes that are required for
the full induction of gluconeogenic gene expression [23]. It is also
possible that the action of E2F1 on gluconeogenesis depends on the
interaction with other transcription factors such as CREB, FOXO1, or
PPARGC1A, that are activated by PKA, and typically dysregulated
during diabetes [2]. In this regard, it has been shown that E2F1 pro-
motes FOXO1 expression in neurons, which could also be a mecha-
nism of gluconeogenic regulation in the liver [24].
The dual phosphorylation of RB1 in hepatocytes both by insulin and by
glucagon seems paradoxical given that in physiological conditions,
depending on the nutritional status, only one signal or the other is
active. This dual activation might not accurately reﬂect the physio-
logical situation in vivo. We could presume that basal E2F1 activity is
regulated during the feeding-fasting cycle by other additional mech-
anisms than the CDK4-RB axis.
Recently, Lee et al. reported that under normal conditions, in the fed
state, CDK4 phosphorylates and activates the acetyltransferase GCN5,
which, in turn, results in the inhibition of PPARGC1A activity and the
decreased expression of its gluconeogenic target genes [25]. This is at
odds with our observations in Cdk4/ hepatocytes (Figure 3E,F and
Suppl. Fig. 3 C-D). Nevertheless, both Lee et al. and our group reported
the hyperphosphorylation of the retinoblastoma protein in the livers of
insulin-resistant mice [12,25]. In addition, hepatic E2F1 expression is
increased during diabetes in both mice and humans (Figure 4A,MOLECULAR METABOLISM 11 (2018) 104e112  2018 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comSuppl. Fig. 4A, and Figure 5A). This indicates that in the diabetic state
there is a pathological hyperactivation of the CDK4-RB1-E2F1 pathway
in the liver that contributes to hyperglycemia. This conclusion is
supported by the fact that speciﬁcally depleting E2F1 in the liver re-
duces gluconeogenesis and decreases hyperglycemia in a diabetic
mouse model (Figure 4 C,D). One possible explanation for the
increased hepatic E2F1 activity during diabetes is the increased
chronic inﬂammation and reticulum stress observed during this
pathological state [26]. Interestingly, increased E2F1 expression and
retinoblastoma protein hyperphosphorylation has also been observed
in the white adipose tissue from obese rodents and humans [27e29].
This suggests that E2F1 activity may also contribute to the patho-
physiology of insulin resistance in other tissues than the liver.
In conclusion, the results presented here, along with our previous
ﬁnding that E2F1 contributes to hepatic steatosis, demonstrate that
this transcription factor critically contributes both to hyperlipidemia and
hyperglycemia during insulin resistance. This suggests that an inter-
esting therapeutic window exists to simultaneously target these two
key metabolic pathways that are abnormally increased in type 2
diabetes.
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